Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.600
+0.050 (1.96%)
At close: Dec 26, 2024, 4:00 PM
2.610
+0.010 (0.38%)
After-hours: Dec 26, 2024, 4:22 PM EST
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $183.00K in the quarter ending September 30, 2024, a decrease of -34.17%. This brings the company's revenue in the last twelve months to $876.00K, up 8.08% year-over-year. In the fiscal year ending March 31, 2024, Vistagen Therapeutics had annual revenue of $1.06M, down -568.72%.
Revenue (ttm)
$876.00K
Revenue Growth
+8.08%
P/S Ratio
89.95
Revenue / Employee
$21,900
Employees
40
Market Cap
72.39M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Prenetics Global | 25.56M |
Generation Bio Co. | 18.58M |
Tonix Pharmaceuticals Holding | 11.29M |
Cue Biopharma | 9.53M |
Clearside Biomedical | 7.70M |
Werewolf Therapeutics | 3.39M |
Ovid Therapeutics | 631.70K |
VTGN News
- 6 weeks ago - Vistagen to Present at the Stifel 2024 Healthcare Conference - Business Wire
- 6 weeks ago - Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire
- 7 weeks ago - Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire
- 7 weeks ago - Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - Business Wire
- 2 months ago - Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha
- 2 months ago - Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - Business Wire
- 3 months ago - Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire